Esketamine Combined Pregabalin and Duloxetine for Postherpetic Neuralgia
ConditionPostherpetic Neuralgia
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorBeijing Tiantan Hospital
About this trial
To assess the 1-week effects and safety of esketamine in combination with pregabalin and duloxetine to relieve pain in patients with postherpetic Neuralgia(PHN).
Eligibility criteria
Qualifiers
Ages more than 18 years;
Pain present for more than 3 months after healing of a herpes zoster skin rash;
Has an average pain score of at least 4 on a Numeric Rating Scale (NRS, 0= no pain, 10= worst possible pain)；
Failed to respond to or tolerate the effective dose of pregabalin monotherapy.
Disqualifiers
Obstructive sleep apnoea syndrome;
Those who receive interventional treatments;
A history of systemic immune diseases, organ transplantation, or cancers;
A history of severe cardiopulmonary, hepatic or renal dysfunction;
Trial design
Treatments tested in this trial
- esketamine group
- control group
Treatment groups
150 Participants
are divided into 2 treatment groupsSponsors and collaborators
Beijing Tiantan Hospital
Lead sponsor
Beijing Xiaotangshan Hospital
Collaborator
The First Hospital of Fangshan District,Beijing
Collaborator
Beijing Ditan Hospital
Collaborator
Hengshui People's Hospital
Collaborator
Source ClinicalTrials.gov